AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

upload.jpg

AdAlta and Cell Therapies Pty Ltd (CTPL) execute a master services agreement

The deal establishes CTPL as AdAlta’s preferred manufacturer of cellular Immunotherapies

MSA also gives AdCella access to deep experience in development and manufacturing of cellular immunotherapies

Special Report: AdAlta has signed a strategic deal designating Cell Therapies (CTPL) as the preferred manufacturing partner for its cellular immunotherapies, further enhancing its AdCella venture.

AdAlta (ASX:1AD) and CTPL have executed a master services agreement (MSA) with initial work anticipated to focus on technical feasibility assessments of 1AD’s in-licensing candidates.

CTPL is Australia’s leading contract manufacturer of cellular immunotherapies for clinical trials and commercial supply.

1AD says the MSA provides AdCella with access to deep experience in development and manufacturing of cellular immunotherapies and state-of-the-art facilities.

Read more: https://stockhead.com.au/health/adalta-secures-cell-therapies-as-cellular-immunotherapies-manufacturer/

Stockhead Reports: AdAlta secures Cell Therapies as cellular immunotherapies manufacturer